Table 1.
LOS = length of stay. RMD = remdesivir
| LOS In Mild COVID-19 Patients | |||
|---|---|---|---|
| Treatment type | Number (n) | Mean | Standard deviation |
| Remdesivir | 47 | 4.723 | 0.423 |
| Remdesivir + dexamethasone | 41 | 4.512 | 0.4529 |
| Dexamethasone | 17 | 3.176 | 0.4529 |
| Others (Hydroxychloroquine/Transfusion/ETC) | 4 | 2.75 | 1.45 |
| p = 0.186 | |||
| LOS In Moderate COVID-19 Patients | |||
| Dexamethasone | 105 | 5.924 | 0.341 |
| Remdesivir | 20 | 6.75 | 0.782 |
| Remdesivir + dexamethasone | 372 | 4.978 | 0.181 |
| Others (Hydroxychloroquine/Transfusion/ETC) | 13 | 6.377 | 4.864 |
| p = 0.007 | |||
| LOS In Severe COVID-19 Patients | |||
| Dexamethasone | 82 | 11.768 | 0.75 |
| Dexa + RMD | 211 | 11.578 | 0.46 |
| Dexa + RMD + Baricitinib | 32 | 10.25 | 1.2 |
| Dexa + RMD + Tocilizumab | 45 | 9.2 | 1.01 |
| Others (Hydroxychloroquine/Transfusion/ETC) | 11 | 17.909 | 2.05 |
| p = 0.0034 | |||
Mild patients are not hypoxic and on room-air only. Moderate patients require nasal cannula for oxygen support. Severe patients need high flow oxygen nasal cannula, PAP, or intubation with mechanical ventilation support to keep oxygen saturation greater than 90%